You haven't searched anything yet.
Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe's growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms.
Ginkgo is a high-growth, well-capitalized public biotech company in Boston that is redesigning the living world to solve some of the globe's growing challenges in health, energy, food, materials, and more. Our mission to "make biology easier to engineer" is poised to disrupt multiple industries by leveraging our innovative data, automation, and scale in biological engineering. Ginkgo has built a platform for "cell engineering" to use AI/ML tools for DNA design, long DNA synthesis and assembly, next-gen sequencing, automated culturing, assay development, high-throughput high-content screening to advance pre-clinical research and development as well as manufacturing process optimization across therapeutic modalities.
Ginkgo is a partner driven company with over 100 programs running on the platform. We are seeking to enable drug-developers but have no designs to develop therapeutics ourselves. Within Ginkgo, the Mammalian Engineering team consists of a set of scientists and engineers with subject matter expertise across cell therapy, gene therapy, rna therapeutics, and biologics. This team is responsible for translating challenges our partners have into actionable R&D programs that leverage the broader Ginkgo platform's resources (aka the Foundry); and then manage and execute on those programs to deliver solutions on time and budget. Ginkgo has a number of public and confidential programs in RNA therapeutics, including developing next generation circular RNA and mRNA constructs with Pfizer, and triggering cell-type specific circularization with . We have also invested in RNA circularization technology through acquisition of Circularis. As a partner-driven platform company we are not focused on any particular therapeutic area and are generally interested in enabling the appropriate pharmacological characteristics for a partner's payload. These efforts blend with our teams' efforts in gene therapy and delivery technologies.
We are looking for a Senior Director, RNA Therapy to continue building and managing our portfolio of RNA therapeutic programs. The ideal candidate will have had experiences both developing RNA platforms and driving preclinical and/or clinical programs with increasing leadership responsibilities throughout their career. The position requires a combination of deep technical understanding, general business acumen, project management skills, superior communication skills, and the ability to grow and lead scientific teams. This is a leadership role reporting to the VP of Mammalian Engineering.
Please note: this role could be based in either our Seaport or Cambridge locations, but requires some flexibility to occasionally be present at the other location.
Responsibilities:
Minimum Requirements:
Preferred Capabilities and Experience
#LI-MB1
Full Time
$152k-182k (estimate)
05/14/2024
06/03/2024
ginkobioworks.com
Boston, MA
<25
Contract Research